Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (17146)	6/20/2005 8:44:45 PM
From: Clarksterh	Respond to of 52153

Mike - In the paper Peter pointed to "the frequencies of certain allelic variants or mutant genes among people who share a geographic origin or culture have medical value" But by targeting, say, blacks for a drug, you are not targeting a phenotype-- That is true. But is also true of most markers. They are very imprecise - just more precise than no marker at all. So marker-of-race is not different in kind from a marker-by-chemistry (think of on-going debate over the fact that there are a significant percentage of people who have elevated LDL but for somewhat unknown reasons (i.e. not predictable) they don't get heart disease and yet they are given statins which have some risk). Both are statistical in nature. Clark